Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Completed · Phase 2

Conditions studied: Kidney Cancer, Melanoma (Skin)

In brief

RATIONALE: Denileukin diftitox may be able to make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with metastatic melanoma or metastatic kidney cancer.

Key facts

Study ID

NCT00082914

Run by

National Cancer Institute (NCI)

Starts

2004-03-01

Expected to finish

2006-07-01

Last updated by the study team

2013-06-20

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• NCI - Center for Cancer Research — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.